Pulling SEC filings + quote and writing the call…
RGC
Regencell Bioscience Holdings Ltd
$13.20
▲ +9.91%$12.01▼ -79.98%
over 1Y
L $10.36EODHDH $78.00
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+9.9%
1W-39.0%
1M-55.5%
3M-55.5%
YTD-41.5%
1Y-80.0%
Avoid
Conviction
Horizon
Long (>12mo)
Pre-revenue micro-cap with no sales, ongoing losses, a tiny $2.4M cash pile and explosive share dilution — not investable.
Regencell Bioscience is a development-stage company in traditional-Chinese-medicine-based therapeutics with no commercial revenue in any year of its history. FY2025 produced an operating loss of -$3.77M and a net loss of -$3.58M, continuing an unbroken string of losses (-$1.35M to -$7.45M across FY2021-FY2025). With no revenue and an accumulated deficit of -$25.2M against just $4.86M of equity, this is a pre-product research enterprise, not an operating business that can be valued on fundamentals.
Sources: SEC EDGAR (CIK 0001829667, latest 4 filed 2026-05-29) · EODHD · analysis by claude-code · as of 6/21/2026, 8:56:10 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.